Search results for "LIVER BIOPSY"

showing 10 items of 152 documents

Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C.

2008

Eosinophilic infiltrate of liver tissue is described in primary cholestatic diseases, hepatic allograft rejection and drug-induced liver injury, but its significance and its implications in chronic hepatitis C are unknown. The aim of this study was to investigate the clinical significance of eosinophilic liver infiltrate in patients with chronic hepatitis C. We retrospectively evaluated 147 patients with chronic hepatitis C. The presence of eosinophilic infiltrate was investigated in liver biopsies, and a numeric count of eosinophilic leucocytes in every portal tract was assessed. An eosinophilic infiltrate of liver tissue (> or =3 cells evaluated in the portal / periportal spaces) was obse…

Liver CirrhosisMalemedicine.medical_specialtyPathologyLiver steatosisSettore MED/08 - Anatomia PatologicaChronic hepatitis CGastroenterologyFibrosisVirologyInternal medicineEosinophiliaEosinophilicHumansMedicineClinical significanceRetrospective StudiesLiver injuryHepatologymedicine.diagnostic_testbusiness.industryLiver fibrosiOdds ratioHepatitis CHepatitis C ChronicLiver biopsymedicine.diseaseEosinophilsFatty LiverInfectious DiseasesLiverLiver biopsyFemaleEosinophilic infiltrateSteatosisDrugChronic hepatitis C; Drugs; Eosinophilic infiltrate; Liver biopsy; Liver fibrosis; Liver steatosisbusiness
researchProduct

The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease.

2020

Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver diseases worldwide, involving about 25% of people. NAFLD incorporates a large spectrum of pathological conditions, from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis and its complications include hepatic decompensation and hepatocellular carcinoma (HCC). This progression occurs, over many years, in an asymptomatic way, until advanced fibrosis appears. Thus, the differentiation of NASH from simple steatosis and identification of advanced hepatic fibrosis are key issues. To date, the histological assessment of fibrosis with liver biopsy is the gold standard, but obviously, invasiveness is the …

Liver Cirrhosismedicine.medical_specialtyCirrhosisCarcinoma HepatocellularBiopsyDiseaseGastroenterology03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineDrug DiscoverymedicineHumansPharmacologymedicine.diagnostic_testbusiness.industryFatty liverLiver Neoplasmsnutritional and metabolic diseasesBiomarkers FibroScan Fibrosis MRE MRI NAFLD NASH Non-invasive testsmedicine.diseasedigestive system diseasesLiver030220 oncology & carcinogenesisLiver biopsyHepatocellular carcinoma030211 gastroenterology & hepatologySteatohepatitisbusinessHepatic fibrosisCurrent pharmaceutical design
researchProduct

Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment.

2013

SummaryLiver fibrosis results from an excessive wound healing response in most chronic liver diseases, such as hepatitis C. Despite great advances in antiviral therapy in recent years, progressive liver fibrosis remains a major problem for patients with recurrent hepatitis C after liver transplantation. Liver biopsy remains a central tool in the management of HCV-positive liver transplant recipients, but reliable non-invasive methods for the assessment of liver fibrosis, such as ultrasound elastography, are increasingly being incorporated in the management of post-transplant patients, helping predict prognosis, guide treatment decisions, and stratify patients for emerging antifibrotic thera…

Liver Cirrhosismedicine.medical_specialtyCirrhosisMacrophagemedicine.medical_treatmentBiopsyLiver transplantationGastroenterologyAntiviral AgentsPost-transplantFibrosisRecurrenceNAFLDInternal medicineMedicineHumansHepatic stellate cellSerum markerHepatitisTransplantationProgressionHepatologymedicine.diagnostic_testbusiness.industryT cellSecond hitHepatitis Cmedicine.diseasePrognosisFibrosisHepatitis CLiver TransplantationTransplantationCirrhosisLiverTGFbetaLiver biopsyHCVHepatic stellate cellDisease ProgressionInterferonElasticity Imaging TechniquesCollagenAntifibroticElastographybusinessJournal of hepatology
researchProduct

Anti-fibrotic therapy: lost in translation?

2012

While preclinical development of potential anti-fibrotics is far advanced, with numerous pharmacological targets and promising agents, almost none has entered clinical validation. Reasons are manifold, including the usually slow progression of liver fibrosis, requiring high numbers of well-stratified patients undergoing long-term treatment when conventional liver biopsy based parameters or hard liver-related endpoints are used. Importantly, there is a notorious lack of sensitive and specific surrogate markers or imaging technologies for liver fibrosis progression or regression that would permit a rapid clinical screening for potential anti-fibrotics. Nonetheless, in view of an urgent need f…

Liver Cirrhosismedicine.medical_specialtyCirrhosisPlacebo-controlled studyAutoimmune hepatitisChronic liver diseaseGastroenterologyPrimary sclerosing cholangitisTranslational Research BiomedicalPrimary biliary cirrhosisFibrosisInternal medicinemedicineAnimalsHumansIntensive care medicineHepatologymedicine.diagnostic_testbusiness.industryPatient Selectionmedicine.diseaseMagnetic Resonance ImagingDisease Models AnimalLiver biopsybusinessBiomarkersJournal of hepatology
researchProduct

Mini-laparoscopy in the endoscopy unit: Safety and outcomes in over one thousand patients

2011

AIM: To investigate the safety of consecutive mini-laparoscopy guided liver biopsies for the diagnosis and staging of liver diseases. METHODS: In this study we retrospectively analyzed the safety of mini-laparoscopic liver biopsy performed in an endoscopy unit in 1071 patients. We measured the incidence of bleeding and evaluated the management and outcome of bleeding interventions. RESULTS: The most common etiologies of liver injury were viral hepatitis and autoimmune liver disease. 250 patients had macroscopically and histologically proven cirrhosis. 13 patients had no pathological findings. 33% of all patients had bleeding that required argon plasma coagulation of the puncture site during…

Liver injurymedicine.medical_specialtyCirrhosismedicine.diagnostic_testbusiness.industryArgon plasma coagulationmedicine.diseaseSurgeryEndoscopyBrief ArticlesLiver diseaseLiver biopsymedicineViral hepatitisLaparoscopybusinessWorld Journal of Gastrointestinal Endoscopy
researchProduct

Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.

2018

Background & Aims: Controlled attenuation parameter (CAP) is a novel non-invasive measure of hepatic steatosis, but it has not been evaluated in alcoholic liver disease. Therefore, we aimed to validate CAP for the assessment of biopsy-verified alcoholic steatosis and to study the effect of alcohol detoxification on CAP. Methods: This was a cross-sectional biopsy-controlled diagnostic study in four European liver centres. Consecutive alcohol-overusing patients underwent concomitant CAP, regular ultrasound, and liver biopsy. In addition, we measured CAP before and after admission for detoxification in a separate single-centre cohort. Results: A total of 562 patients were included in the s…

MaleAlcoholic liver diseasemedicine.medical_treatmentBiopsyGastroenterologyCohort StudiesSensitivity0302 clinical medicineInterquartile rangeRisk FactorsAlcohol detoxificationNon-invasiveSteatohepatitisUltrasonography2. Zero hungerMetabolic Syndromemedicine.diagnostic_testAlcohol AbstinenceFatty liverAlcohol detoxificationDiagnostic testMiddle Aged3. Good healthAlcoholismLiver030220 oncology & carcinogenesisLiver biopsyControlled attenuation parameterSpecificityElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleFatty Liver AlcoholicAdultmedicine.medical_specialty03 medical and health sciencesPredictive Value of TestsFatty liverInternal medicinemedicineHumansFibroScanHepatologybusiness.industryAlcoholic liver diseasemedicine.diseaseCross-Sectional StudiesConcomitantSteatohepatitisSteatosisbusinessJournal of hepatology
researchProduct

Unexplained chronic liver disease in Ethiopia: a cross-sectional study

2018

Background Hepatitis B virus (HBV) infection is assumed to be the major cause of chronic liver disease (CLD) in sub-Saharan Africa. The contribution of other aetiological causes of CLD is less well documented and hence opportunities to modulate other potential risk factors are being lost. The aims of this study were to explore the aetiological spectrum of CLD in eastern Ethiopia and to identify plausible underlying risk factors for its development. Methods A cross-sectional study was undertaken between April 2015 and April 2016 in two public hospitals in Harar, eastern Ethiopia. The study population comprised of consenting adults with clinical and radiological evidence of chronic liver dise…

MaleCross-sectional studyEpidemiologyBiopsyChronic liver disease0302 clinical medicineRisk FactorsKhatEpidemiologyPrevalenceSIMPLE NONINVASIVE INDEX030212 general & internal medicineViral hepatitisPOPULATIONbiologymedicine.diagnostic_testSub-Saharan AfricaLiver DiseasesGastroenterologyCHRONIC HEPATITISGeneral MedicineAlcoholismLiverLiver biopsyPopulation studyFemale030211 gastroenterology & hepatologyC HEPATITISViral hepatitisLife Sciences & BiomedicineResearch ArticleAdultmedicine.medical_specialtySubstance-Related DisordersAcute Lung InjuryKHAT LEAVESAUTOIMMUNEVERBAL AUTOPSY METHODCathaVIRUS-INFECTIONCatha edulis03 medical and health sciencesInternal medicinemedicineHumanslcsh:RC799-869Science & TechnologyGastroenterology & HepatologySIGNIFICANT FIBROSISbusiness.industryHepatotoxicity1103 Clinical SciencesHepatologybiology.organism_classificationmedicine.diseaseCross-Sectional StudiesChronic Diseaselcsh:Diseases of the digestive system. GastroenterologyEthiopiabusiness
researchProduct

Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients

2006

To report on our large German collective and updated data of 142 patients with autoimmune hepatitis (AIH) type 1.Key investigations performed were liver biopsy, serum autoantibodies as well as serum markers such as IgG and elevated transaminases. Antinuclear antigen (ANA) and smooth muscle antigen (SMA) autoantibodies characterized type 1 AIH. Type 3 (AIH) was solely characterized by the occurrence of soluble liver antigen/liver-pancreas antigen (SLA/LP) autoantibodies either with or without ANA or SMA autoantibodies.Most prevalent HLAs were A2 (68 patients, 48%), B8 (63 patients, 44%), C7 (90 patients, 63%), DR3 (49 patients, 38%), DR4 (49 patients, 38%) and DQ2 (42 patients, 30%). Compare…

MaleImmunogeneticsAutoimmune hepatitisHuman leukocyte antigenAutoantigensHLA-B8 AntigenHLA-DR3 AntigenAntigenimmune system diseasesHLA AntigensGermanyHLA-DQ AntigensmedicineHumansHLA-DQ Antigenmedicine.diagnostic_testbusiness.industryGastroenterologyAutoantibodyGeneral Medicinemedicine.diseasePrognosisdigestive system diseasesHepatitis AutoimmuneGene Expression RegulationItalyLiver biopsyImmunologyNorth AmericaElevated transaminasesFemalebusinessRapid Communication
researchProduct

Could JC virus provoke metastasis in colon cancer?

2014

AIM: To evaluate the prevalence of John Cunningham virus (JC virus) in a small cohort of patients with colon cancer and to assess its presence in hepatic metastasis. METHODS: Nineteen consecutive patients with histologically diagnosed colon cancer were included in our study, together with ten subjects affected by histologically and serologically diagnosed hepatitis C virus infection. In the patients included in the colon cancer group, JC virus was searched for in the surgical specimen; in the control group, JC virus was searched for in the hepatic biopsy. The difference in the prevalence of JC virus in the hepatic biopsy between the two groups was assessed through the χ2 test. RESULTS: Four…

MalePathologymedicine.medical_specialtyColorectal cancerHepatitis C virusvirusesBiopsyJC virusmedicine.disease_causePolymerase Chain ReactionVirusMetastasisRisk FactorsmedicinePrevalenceHumansAgedNeoplasm StagingRetrospective StudiesAged 80 and overSettore MED/12 - GastroenterologiaPolyomavirus InfectionsChi-Square Distributionmedicine.diagnostic_testbusiness.industryLiver NeoplasmsGastroenterologyJC Virus InfectionGeneral MedicineHepatitis CCase Control StudyMiddle Agedmedicine.diseaseJC VirushumanitiesSettore MED/18 - Chirurgia GeneraleTumor Virus InfectionsItalyLiver biopsyColonic NeoplasmsDNA ViralFemalecolon cancer John Cunnungham virus metastasisbusiness
researchProduct

Liver failure caused by light chain deposition disease associated with multiple myeloma.

2012

Acute liver failure is an unusual complication in multiple myeloma. Here, we report a case of multiple myeloma with light chain deposition disease (LCDD) that presented with progressive jaundice due to intrahepatic cholestasis. Diagnosis was made after liver biopsy that showed deposition of kappa light chains occupying perisinusoidal spaces. The patient developed encephalopathy and liver failure and died despite prompt initiation of dexamethasone therapy. The current prognosis of multiple myeloma patients with liver failure due to LCDD is dismal. New therapeutic strategies might improve this condition.

MalePathologymedicine.medical_specialtyEncephalopathyParaproteinemiasCholestasis IntrahepaticImmunoglobulin light chainLight chain deposition diseaseImmunoglobulin kappa-ChainsFatal OutcomeCholestasisInternal MedicineMedicineHumansMultiple myelomaAgedAged 80 and overmedicine.diagnostic_testbusiness.industryGeneral MedicineJaundiceLiver Failure Acutemedicine.diseaseLiver biopsyHepatic Encephalopathymedicine.symptomComplicationbusinessMultiple MyelomaInternal medicine (Tokyo, Japan)
researchProduct